The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Stem-Like Cells in Bone Sarcomas: Implications for Tumorigenesis
Open accessAbstract
Bone sarcomas are a clinically and molecularly heterogeneous group of malignancies characterized by varying degrees of mesenchymal differentiation. Despite advances in medical and surgical management, survival rates for high-grade tumors have remained static at 50% to 70%. Tumor stem cells have been recently implicated in the pathogenesis of other heterogeneous, highly malignant tumors. We demonstrate here the existence of a small subpopulation of self-renewing bone sarcoma cells that are capable of forming suspended spherical, clonal colonies, also called "sarcospheres," in anchorage-independent, serum-starved conditions. These bone sarcoma cells as well as tissue specimens express activated STAT3 and the marker genes of pluripotent embryonic stem (ES) cells, Oct 3/4 and Nanog. Expression levels of Oct 3/4 and Nanog are greater in sarcospheres than in adherent cultures. A subset of bone sarcoma cells displays several surface markers of mesenchymal stem cells (Stro-1, CD105, and CD44) as well as attributes of mesodermal, ectodermal, and endodermal differentiation. Although previously documented in brain and breast tumors, our results support the extension of the cancer stem cell hypothesis to include tumors of mesenchymal lineage. Furthermore, they suggest the participation of ES cell homeobox proteins in non-germ cell tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multilineage potential of adult human mesenchymal stem cells
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., & Marshak, D. R. (1999) · Science · doi:10.1126/science.284.5411.143 · Cited by 21,052
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Identification of human brain tumour initiating cells
Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., Henkelman, R. M., Cusimano, M. D., & Dirks, P. B. (2004) · Nature · doi:10.1038/nature03128 · Cited by 7,433
Bonnet, D., & Dick, J. E. (1997) · Nature Medicine · doi:10.1038/nm0797-730 · Cited by 5,864
Reynolds, B. A., & Weiss, S. (1992) · Science · doi:10.1126/science.1553558 · Cited by 4,482
Functional Expression Cloning of Nanog, a Pluripotency Sustaining Factor in Embryonic Stem Cells
Chambers, I., Colby, D., Robertson, M., Nichols, J., Lee, S., Tweedie, S., & Smith, A. (2003) · Cell · doi:10.1016/s0092-8674(03)00392-1 · Cited by 3,255
The Homeoprotein Nanog Is Required for Maintenance of Pluripotency in Mouse Epiblast and ES Cells
Mitsui, K., Tokuzawa, Y., Itoh, H., Segawa, K., Murakami, M., Takahashi, K., Maruyama, M., Maeda, M., & Yamanaka, S. (2003) · Cell · doi:10.1016/s0092-8674(03)00393-3 · Cited by 3,191
Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma
Galli, R., Binda, E., Orfanelli, U., Cipelletti, B., Gritti, A., De Vitis, S., Fiocco, R., Foroni, C., Dimeco, F., & Vescovi, A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1364 · Cited by 2,570
Cancerous stem cells can arise from pediatric brain tumors
Hemmati, H. D., Nakano, I., Lazareff, J. A., Masterman-Smith, M., Geschwind, D. H., Bronner-Fraser, M., & Kornblum, H. I. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2036535100 · Cited by 1,817
Cited by
Identification and expansion of the tumorigenic lung cancer stem cell population
Eramo, A., Lotti, F., Sette, G., Pilozzi, E., Biffoni, M., Di Virgilio, A., Conticello, C., Ruco, L., Peschle, C., & De Maria, R. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402283 · Cited by 1,707
The Biology of Cancer Stem Cells
Lobo, N. A., Shimono, Y., Qian, D., & Clarke, M. F. (2007) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.22.010305.104154 · Cited by 1,043
Røsland, G. V., Svendsen, A., Torsvik, A., Sobala, E., McCormack, E., Immervoll, H., Mysliwietz, J., Tonn, J.-C., Goldbrunner, R., Lønning, P. E., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4630 · Cited by 644
CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells
Wang, J., Sakariassen, P. Ø., Tsinkalovsky, O., Immervoll, H., Bøe, S. O., Svendsen, A., Prestegarden, L., Røsland, G., Thorsen, F., Stuhr, L., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23130 · Cited by 567
Tirino, V., Desiderio, V., Paino, F., De Rosa, A., Papaccio, F., La Noce, M., Laino, L., De Francesco, F., & Papaccio, G. (2013) · The FASEB Journal · doi:10.1096/fj.12-218222 · Cited by 395
McLean, K., Gong, Y., Choi, Y., Deng, N., Yang, K., Bai, S., Cabrera, L., Keller, E., McCauley, L., Cho, K. R., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45273 · Cited by 380
Chemotherapy resistance in osteosarcoma: current challenges and future directions
Chou, A. J., & Gorlick, R. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.7.1075 · Cited by 377
Osteosarcoma Development and Stem Cell Differentiation
Tang, N., Song, W.-X., Luo, J., Haydon, R. C., & He, T.-C. (2008) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-008-0335-z · Cited by 357
Functional Evidence that the Self-Renewal Gene NANOG Regulates Human Tumor Development
Jeter, C. R., Badeaux, M., Choy, G., Chandra, D., Patrawala, L., Liu, C., Calhoun-Davis, T., Zaehres, H., Daley, G. Q., & Tang, D. G. (2009) · Stem Cells · doi:10.1002/stem.29 · Cited by 335
Reactive Oxygen Species in Cancer Stem Cells
Shi, X., Zhang, Y., Zheng, J., & Pan, J. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4529 · Cited by 325
Cancer stem cells in osteosarcoma
Brown, H. K., Tellez-Gabriel, M., & Heymann, D. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.11.019 · Cited by 303
Highlighted STAT3 as a potential drug target for cancer therapy
Lee, H., Jeong, A. J., & Ye, S.-K. (2019) · BMB Reports · doi:10.5483/bmbrep.2019.52.7.152 · Cited by 295
Detection and Characterization of CD133+ Cancer Stem Cells in Human Solid Tumours
Tirino, V., Desiderio, V., d'Aquino, R., De Francesco, F., Pirozzi, G., Galderisi, U., Cavaliere, C., De Rosa, A., & Papaccio, G. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003469 · Cited by 287
Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention
Xiong, A., Yang, Z., Shen, Y., Zhou, J., & Shen, Q. (2014) · Cancers · doi:10.3390/cancers6020926 · Cited by 283
Therapy for Osteosarcoma: Where Do We Go From Here?
Chou, A. J., Geller, D. S., & Gorlick, R. (2008) · Pediatric Drugs · doi:10.2165/00148581-200810050-00005 · Cited by 274
Molecular Pathogenesis of Osteosarcoma
Kansara, M., & Thomas, D. M. (2007) · DNA and Cell Biology · doi:10.1089/dna.2006.0505 · Cited by 273
Aldehyde Dehydrogenase as a Marker for Stem Cells
Moreb, J. (2008) · Current Stem Cell Research & Therapy · doi:10.2174/157488808786734006 · Cited by 272
Adhikari, A. S., Agarwal, N., Wood, B. M., Porretta, C., Ruiz, B., Pochampally, R. R., & Iwakuma, T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3463 · Cited by 261
Mechanisms of Disease: Cancer stem cells--targeting the evil twin
Trumpp, A., & Wiestler, O. D. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1110 · Cited by 199
Zheng, Y., Wang, G., Chen, R., Hua, Y., & Cai, Z. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-0780-x · Cited by 127
Safety Concern between Autologous Fat Graft, Mesenchymal Stem Cell and Osteosarcoma Recurrence
Perrot, P., Rousseau, J., Bouffaut, A.-L., Rédini, F., Cassagnau, E., Deschaseaux, F., Heymann, M.-F., Heymann, D., Duteille, F., Trichet, V., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010999 · Cited by 120
Rainusso, N., Brawley, V. S., Ghazi, A., Hicks, M. J., Gottschalk, S., Rosen, J. M., & Ahmed, N. (2012) · Cancer Gene Therapy · doi:10.1038/cgt.2011.83 · Cited by 114
Aran, V., Devalle, S., Meohas, W., Heringer, M., Cunha Caruso, A., Pinheiro Aguiar, D., Leite Duarte, M. E., & Moura Neto, V. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103340 · Cited by 87
Palmer, N. P., Schmid, P. R., Berger, B., & Kohane, I. S. (2012) · Genome Biology · doi:10.1186/gb-2012-13-8-r71 · Cited by 86
Avril, P., Le Nail, L.-R., Brennan, M. Á., Rosset, P., De Pinieux, G., Layrolle, P., Heymann, D., Perrot, P., & Trichet, V. (2016) · Journal of Bone Oncology · doi:10.1016/j.jbo.2015.11.002 · Cited by 38
Avnet, S., Lemma, S., Cortini, M., Di Pompo, G., Perut, F., & Baldini, N. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00305 · Cited by 29
Hernigou, P., Flouzat Lachaniette, C. H., Delambre, J., Chevallier, N., & Rouard, H. (2014) · International Orthopaedics · doi:10.1007/s00264-014-2384-0 · Cited by 22
“A major concern today in the application of regenerative therapies after cancer, especially cell-based therapies, is whether these new treatments will increase the risk of local tumour recurrence, particularly at the site of a tumour resection [16].”
BackgroundManagement of Refractory Pediatric Sarcoma: Current Challenges and Future Prospects
Pushpam, D., Garg, V., Ganguly, S., & Biswas, B. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s193363 · Cited by 16
Avril, P., Duteille, F., Ridel, P., Heymann, M.-F., De Pinieux, G., Rédini, F., Blanchard, F., Heymann, D., Trichet, V., & Perrot, P. (2016) · Plastic and Reconstructive Surgery · doi:10.1097/01.prs.0000479989.88114.8b · Cited by 12
Metadata
- Authors
- Gibbs, C. P., Kukekov, V. G., Reith, J. D., Tchigrinova, O., Suslov, O. N., Scott, E. W., Ghivizzani, S. C., Ignatova, T. N., & Steindler, D. A.
- Venue
- Neoplasia
- Publisher
- Elsevier BV
- Published
- 2005-11
- Volume
- 7
- Issue
- 11
- Pages
- 967-976
- ISSN
- 1476-5586 (ISSN-L)
- OpenAlex
- W2018429029
- Cited by
- 492
- References
- 29
- FWCI
- 10.46
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.